The Inter-rater Reliability of the Turkish Version of Aphasia Rapid Test for Stroke

February 20, 2022 updated by: Mariam Kavakci, Ankara City Hospital Bilkent
The Aphasia Rapid Test (ART) is a bedside aphasia screening test developed originally in French. The purpose of this study is to assess the inter-rater reliability of the Turkish version of the ART in stroke patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The Aphasia Rapid Test (ART) was developed and validated originally in French to evaluate language skills in post-stroke patients (Azuar et al., 2013). It is a 26-point scale that takes less than 3 minutes to administer. The simplicity of the ART allows it be used bedside in acute post-stroke patients with little to no training needed. The items needed to administer the ART are also easy to access in healthcare settings (e.g., watch, pen, doctor's coat). Although the ART is not a diagnostic test, it is beneficial for tracking progress and determining prognosis in stroke patients.

The original ART was designed similar to the NIH Stroke Scale (NIHSS), a widely-used test in stroke patients. The NIHSS which assesses many areas of functioning (level of consciousness, gaze, visual ability, facial palsy, motor and sensory ability, limb ataxia, language, dysarthria, and extinction and inattention) was chosen because of its sensitivity to early changes in neurological status and high prognostic accuracy (http://www.nihstrokescale.org). The ART is an expanded version of the language section of the NIHSS. The total possible points on the ART is 26, which indicates the highest level of impairment. The test begins with the patient being asked to follow two one-step commands (up to two points each), a complex command (up to 3 points), repeat three nouns (up to 6 points), repeat a simple sentence (up to 2 points), and name three simple objects (up to 6 points). The next item requires a rating of dysarthria by the examiner (up to 3 points). On the final item, the patient is asked to name as many animals as they can think of in one minute (up to 4 points). With the exception of items 1a, 1b, and 6, there are no time restrictions on the test.

The purpose of the present study is to translate the original ART into Turkish to provide an efficient method for the evaluation of language skills in post-stroke Turkish-speaking patients and to assess its inter-rater reliability.

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ankara, Turkey
        • Ankara City Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

The study population will consist of left MCA stroke patients who experienced a CVA within the last 10 days. These patients will consist of males and females with a minimum age of 18.

Description

Inclusion Criteria:

  • Left MCA infarct due to CVA
  • Right hand dominant
  • Turkish as first language
  • CVA within the last 10 days

Exclusion Criteria:

  • Right or bilateral brain lesion
  • Previous stroke
  • Psychiatric disorder
  • Other neurological disorder
  • Cognitive impairment
  • Endotracheal entubation prohibiting responses to test

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Aphasics
Patients with a left MCA infarct due to CVA will be included in the study. Each subject will be administered an aphasia screening test less than 3 minutes in length. The same test will be administered by another clinician to the same patient within a maximum of 12 hours to assess the inter-rater reliability of the test.
Same

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Inter-rater reliability
Time Frame: The test will be administered within a time frame of 12 hours by two clinicians
The inter-rater reliability between two clinicians administering the same test
The test will be administered within a time frame of 12 hours by two clinicians

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Mariam Kavakci, PhD, Ankara City Hospital Bilkent

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2020

Primary Completion (Actual)

May 1, 2021

Study Completion (Actual)

May 1, 2021

Study Registration Dates

First Submitted

May 9, 2020

First Submitted That Met QC Criteria

May 9, 2020

First Posted (Actual)

May 13, 2020

Study Record Updates

Last Update Posted (Actual)

February 22, 2022

Last Update Submitted That Met QC Criteria

February 20, 2022

Last Verified

February 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Aphasia

  • Teachers College, Columbia University
    Recruiting
    Aphasia | Aphasia, Acquired | Aphasia, Broca | Aphasia Non Fluent | Aphasia, Anomic | Aphasia Following Cerebral Infarction | Aphasia, Mixed | Aphasia, Expressive | Aphasia, Conduction | Aphasia, Rehabilitation
    United States
  • University of California, Berkeley
    University of California, San Francisco; National Institute on Deafness and... and other collaborators
    Recruiting
    Aphasia | Aphasia, Acquired | Aphasia Following Cerebral Infarction | Aphasia, Non-fluent | Aphasia, Fluent | Aphasia Following Nontraumatic Intracerebral Hemorrhage
    United States
  • University of South Carolina
    National Institute on Deafness and Other Communication Disorders (NIDCD)
    Completed
    Stroke | Aphasia | Stroke, Ischemic | Aphasia, Broca | Aphasia, Anomic | Aphasia, Global | Aphasia, Fluent | Aphasia, Mixed | Aphasia, Jargon | Aphasia, Expressive | Aphasia, Conduction
    United States
  • Maya Henry
    National Institute on Aging (NIA)
    Recruiting
    Logopenic Variant Primary Progressive Aphasia | Progressive Aphasia | Logopenic Progressive Aphasia (LPA) | Primary Progressive Aphasia(PPA) | Logopenic Variant of Primary Progressive Aphasia (LPA) | Progressive Aphasia in Alzheimer's Disease
    United States
  • Maya Henry
    National Institutes of Health (NIH); National Institute on Aging (NIA)
    Recruiting
    Semantic Dementia | Logopenic Progressive Aphasia | Nonfluent Aphasia, Progressive | Logopenic Variant Primary Progressive Aphasia | Semantic Variant Primary Progressive Aphasia (svPPA) | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Progressive Aphasia | Logopenic Progressive Aphasia... and other conditions
    United States
  • University of Texas at Austin
    University of California, San Francisco; National Institute on Deafness and...
    Active, not recruiting
    Primary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, Progressive
    United States
  • University of Texas at Austin
    National Institute on Deafness and Other Communication Disorders (NIDCD)
    Enrolling by invitation
    Primary Progressive Aphasia | Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Semantic Memory Disorder | Nonfluent Aphasia, Progressive | Aphasia, Progressive
    United States
  • Institute for Bioengineering of Catalonia
    Hospital Universitari Joan XXIII de Tarragona.; Universitat Pompeu Fabra
    Completed
    Aphasia | Aphasia, Broca | Aphasia, Wernicke | Aphasia, Fluent | Aphasia, Nonfluent
    Spain
  • Dr. Ram Manohar Lohia Hospital
    Not yet recruiting
    Aphasia, Acquired | Aphasia Following Cerebral Infarction | Post Stroke Aphasia | Acute Ischemic Cerebrovascular Disease
    India
  • Flint Rehabilitation Devices, LLC
    University of Texas
    Completed
    Broca Aphasia
    United States

Clinical Trials on Turkish Aphasia Rapid Test

Subscribe